TY - JOUR
T1 - Reducing potentially inappropriate polypharmacy at a national and international level
T2 - the impact of deprescribing networks
AU - McDonald, Emily G.
AU - Lundby, Carina
AU - Thompson, Wade
AU - Boyd, Cynthia
AU - Farrell, Barbara
AU - Gagnon, Camille
AU - Herbin, Jennie
AU - Khuong, Ninh
AU - Moriarty, Frank
AU - Pierson, Tiphaine
AU - Scott, Sion
AU - Scott, Ian A.
AU - Silvius, Jim
AU - Spinewine, Anne
AU - Steinman, Michael A.
AU - Tannenbaum, Cara
AU - Trimble, Johanna
AU - Turner, Justin P.
AU - Reeve, Emily
N1 - Publisher Copyright:
© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2024
Y1 - 2024
N2 - Introduction: Over the past decade, polypharmacy has increased dramatically. Measurable harms include falls, fractures, cognitive impairment, and death. The associated costs are massive and contribute substantially to low-value health care. Deprescribing is a promising solution, but there are barriers. Establishing a network to address polypharmacy can help overcome barriers by connecting individuals with an interest and expertise in deprescribing and can act as an important source of motivation and resources. Areas covered: Over the past decade, several deprescribing networks were launched to help tackle polypharmacy, with evidence of individual and collective impact. A network approach has several advantages; it can spark interest, ideas and enthusiasm through information sharing, meetings and conversations with the public, providers, and other key stakeholders. In this special report, the details of how four deprescribing networks were established across the globe are detailed. Expert opinion: Networks create links between people who lead existing and/or budding deprescribing practices and policy initiatives, can influence people with a shared passion for deprescribing, and facilitate sharing of intellectual capital and tools to take initiatives further and strengthen impact. This report should inspire others to establish their own deprescribing networks, a critical step in accelerating a global deprescribing movement.
AB - Introduction: Over the past decade, polypharmacy has increased dramatically. Measurable harms include falls, fractures, cognitive impairment, and death. The associated costs are massive and contribute substantially to low-value health care. Deprescribing is a promising solution, but there are barriers. Establishing a network to address polypharmacy can help overcome barriers by connecting individuals with an interest and expertise in deprescribing and can act as an important source of motivation and resources. Areas covered: Over the past decade, several deprescribing networks were launched to help tackle polypharmacy, with evidence of individual and collective impact. A network approach has several advantages; it can spark interest, ideas and enthusiasm through information sharing, meetings and conversations with the public, providers, and other key stakeholders. In this special report, the details of how four deprescribing networks were established across the globe are detailed. Expert opinion: Networks create links between people who lead existing and/or budding deprescribing practices and policy initiatives, can influence people with a shared passion for deprescribing, and facilitate sharing of intellectual capital and tools to take initiatives further and strengthen impact. This report should inspire others to establish their own deprescribing networks, a critical step in accelerating a global deprescribing movement.
KW - Deprescribing
KW - medication appropriateness
KW - medication overload
KW - network
KW - polypharmacy
UR - http://www.scopus.com/inward/record.url?scp=85193755041&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85193755041&partnerID=8YFLogxK
U2 - 10.1080/17512433.2024.2355270
DO - 10.1080/17512433.2024.2355270
M3 - Article
C2 - 38739460
AN - SCOPUS:85193755041
SN - 1751-2433
VL - 17
SP - 433
EP - 440
JO - Expert Review of Clinical Pharmacology
JF - Expert Review of Clinical Pharmacology
IS - 5-6
ER -